Gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure
In recent years, academic publishing excited a considerable interest in gut microbiota and its role in human health maintenance. In patients with chronic renal failure, gut microbiota is altered due to increased blood urea nitrogen and metabolic acidosis, specific diet and therapy, as well as prol...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Bosnian |
| Published: |
University of East Sarajevo
2018-12-01
|
| Series: | Biomedicinska istraživanja |
| Subjects: | |
| Online Access: | http://www.biomedicinskaistrazivanja.com/wp-content/uploads/2018/12/09-Mitrovic.pdf |
| _version_ | 1811249115059716096 |
|---|---|
| author | Miloš Mitrović Nada Dimković |
| author_facet | Miloš Mitrović Nada Dimković |
| author_sort | Miloš Mitrović |
| collection | DOAJ |
| description | In recent years, academic publishing excited a considerable interest in gut microbiota and its role in human
health maintenance. In patients with chronic renal failure, gut microbiota is altered due to increased blood
urea nitrogen and metabolic acidosis, specific diet and therapy, as well as prolonged intestinal transit time. Protein-fermenting bacteria such as E. coli, Bacteroides and Ruminicoccus spp dominate gut microbiota in patients
with chronic renal failure. Therefore, the key nephro- and cardiovascular toxins, such as indoxyl-sulfate (IS) and
p-cresyl-sulfate (PCS) are produced in the gut mucosa. The important impact of increased serum levels of IS and
PCS on cardiovascular comorbidity and further deterioration of renal function has been witnessed by numerous observational and animal studies.
There are several therapeutic strategies for lowering serum levels of IS and PCS as well as their toxic effect. The
use of synbiotics, pre- and probiotics, in order to modulate gut microbiota is the most optimal solution currently used. Probiotic cultures of Bifidobacter and Lactobacillus have presented themselves as the ones with the
greatest potential to limit the growth of protein-fermenting bacteria responsible for the production of uremic
toxins. Nevertheless, there is still a need for more well-designed prospective interventional studies, as well as
for controls with well-defined diet restrictions, in order to establish definitive value of this kind of therapy in
patients with chronic renal failure. |
| first_indexed | 2024-04-12T15:39:46Z |
| format | Article |
| id | doaj.art-3674939f6d0a410c9a39065caaf16b11 |
| institution | Directory Open Access Journal |
| issn | 1986-8529 1986-8537 |
| language | Bosnian |
| last_indexed | 2024-04-12T15:39:46Z |
| publishDate | 2018-12-01 |
| publisher | University of East Sarajevo |
| record_format | Article |
| series | Biomedicinska istraživanja |
| spelling | doaj.art-3674939f6d0a410c9a39065caaf16b112022-12-22T03:26:49ZbosUniversity of East SarajevoBiomedicinska istraživanja1986-85291986-85372018-12-019120220610.7251/BII1802202MGut microbiota and uremic toxins produced in intestines in patients with chronic renal failureMiloš Mitrović0Nada Dimković1Zvezdara University Medical Center, Clinical Department of Renal Diseases and Metabolic Disorders with Dialysis “Prof. dr Vasilije Jovanović”, Belgrade, Serbia University of Belgrade, School of Medicine, Belgrade, Serbia In recent years, academic publishing excited a considerable interest in gut microbiota and its role in human health maintenance. In patients with chronic renal failure, gut microbiota is altered due to increased blood urea nitrogen and metabolic acidosis, specific diet and therapy, as well as prolonged intestinal transit time. Protein-fermenting bacteria such as E. coli, Bacteroides and Ruminicoccus spp dominate gut microbiota in patients with chronic renal failure. Therefore, the key nephro- and cardiovascular toxins, such as indoxyl-sulfate (IS) and p-cresyl-sulfate (PCS) are produced in the gut mucosa. The important impact of increased serum levels of IS and PCS on cardiovascular comorbidity and further deterioration of renal function has been witnessed by numerous observational and animal studies. There are several therapeutic strategies for lowering serum levels of IS and PCS as well as their toxic effect. The use of synbiotics, pre- and probiotics, in order to modulate gut microbiota is the most optimal solution currently used. Probiotic cultures of Bifidobacter and Lactobacillus have presented themselves as the ones with the greatest potential to limit the growth of protein-fermenting bacteria responsible for the production of uremic toxins. Nevertheless, there is still a need for more well-designed prospective interventional studies, as well as for controls with well-defined diet restrictions, in order to establish definitive value of this kind of therapy in patients with chronic renal failure.http://www.biomedicinskaistrazivanja.com/wp-content/uploads/2018/12/09-Mitrovic.pdf gut microbiotachronic renal failureuremic toxins |
| spellingShingle | Miloš Mitrović Nada Dimković Gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure Biomedicinska istraživanja gut microbiota chronic renal failure uremic toxins |
| title | Gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure |
| title_full | Gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure |
| title_fullStr | Gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure |
| title_full_unstemmed | Gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure |
| title_short | Gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure |
| title_sort | gut microbiota and uremic toxins produced in intestines in patients with chronic renal failure |
| topic | gut microbiota chronic renal failure uremic toxins |
| url | http://www.biomedicinskaistrazivanja.com/wp-content/uploads/2018/12/09-Mitrovic.pdf |
| work_keys_str_mv | AT milosmitrovic gutmicrobiotaanduremictoxinsproducedinintestinesinpatientswithchronicrenalfailure AT nadadimkovic gutmicrobiotaanduremictoxinsproducedinintestinesinpatientswithchronicrenalfailure |